Vaccines, Blood & Biologics
-
2012 Safety and Availability Communications
This webpage was developed to provide the public with important information about the safety and availability of biological products.
-
FDA Safety Communication: Updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products FDA Safety Communication: Safety risk from tissue recovered at the Pacific Coast Tissue Bank of Los Angeles, California Expiration Date Extension for North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin) Lot 4030026 Through October 31, 2013 FDA Safety Communication: Safety risk from reproductive tissue at the Center for Reproductive Medicine of Lutz, Florida Extension of Expiration Date for Black Widow Spider Antivenin Lot 0667018 (in packaged lot 0585Z) until February 12, 2013 And Instructions for Diluent Use Biologics Product Shortages Q&A Frequently Asked Questions about Minimally Manipulated, Unrelated Cord Blood Products for Clinical Use How FDA Ensures the Safety of Blood Products
-
-
-
